We describe the case of a 73-year-old woman with secondary myelofibrosis who developed subcutaneous extramedullary hematopoiesis. Although extramedullary hematopoiesis has been generally observed in primary myelofibrosis, in this case it was seen in myelofibrosis secondary to polycythemia vera. Histological examination of the subcutaneous nodule revealed that the lesion included cells from the myeloid and megakaryocytic series. The skin lesion almost disappeared after treatment with hydroxyurea. We report here this rare manifestation in secondary myelofibrosis including a review of literature.
Background: PAR-3 is one of the PAR proteins, previously named ASIP, which are indispensable for the establishment of cell polarity in the embryo as well as differentiated epithelial cells. In mammalian epithelial cells, it forms a ternary complex with aPKC and PAR-6, and is localized to the tight junction that has been suggested as being important for creating cell polarity.
We report on a patient with chronic myelogenous leukemia who developed bronchiolitis obliterans organizing pneumonia (BOOP) after allogeneic bone marrow transplantation (BMT). A 19-year-old Japanese male complained of dry cough and dyspnea 7 months after BMT. The chest X-ray and computed tomography revealed patchy infiltrates bilaterally. Lung function test, lung biopsy and bronchoalveolar lavage were consistent with the diagnosis of BOOP. The patient also suffered from suspected graft-versus-host disease (GVHD) of the liver, after discontinuation of cyclosporine. Furthermore, prednisolone proved effective against the BOOP and the liver dysfunction.These findings indicate that BOOP is a possible pulmonary manifestation of chronic GVHD, and that immunological mechanisms may have effected the onset of BOOP after BMT in this case. Keywords
All-trans retinoic acid (ATRA) is widely used as a differentiation therapy to induce a complete remission in patients with acute promyelocytic leukemia (APL) [1]. The major adverse effect during ATRA therapy is an increase of leukocytes, which is often accompanied by retinoic acid syndrome [2]. This reaction is characterized by fever, respiratory distress, radiographic pulmonary infiltrates, pleural effusions, and weight gain [3]. It has also been reported that ATRA-associated neurological symptoms such as headache and pseudotumor cerebri [4] are mainly caused by intracranial hypertension. We describe a patient who developed multiple mononeuropathies during ATRA therapy for APL.A 23-year-old Japanese female was admitted with fever and purpura in November 1997. APL with disseminated intravascular coagulation was diagnosed. She received ATRA (45 mg/m 2 /day) with chemotherapy including daunorubicin (40 mg/m 2 /day, on days 9, 10, 21, and 22) and behenoyl cytarabine (200 mg/m 2 /day, on days 9, 10, 11, 21, 22, and 23), and supportive therapy for disseminated intravascular coagulation. She had a slight headache after administration of ATRA, but there were no findings on the neurological examination and computed tomography scan of the brain. On the seventeenth day after admission, a neurosurgical operation was performed because of acute subdural hematoma. Although ATRAassociated headache persists, no symptoms remained, which were caused by intracranial hemorrhage and operation. Furthermore, she complained of diplopia, and burning pain and contact dysaesthesiae at the dorsum of the left hand and the right foot on day 21 of the ATRA treatment. She also had weakness in the same extremities. Tendon reflexes were normal. Electrophysiologic study revealed a decrease of right peroneal nerve conduction velocity and amplitude. Although right abducens nerve palsy and visual disturbance were present, there were no papilloedema and abnormalities on magnetic resonance imaging of the brain. Lumbar puncture showed normal cerebrospinal fluid with normal pressure. She had no manifestation of autonomic disturbances. ATRA was discontinued because a complete remission was achieved on day 51 after administration of ATRA. Total dosage of ATRA was 3,390 mg. She received three times the intensive postremission chemotherapy (daunorubicin, cytarabine, mitoxantrone, mercaptopurine, and prednisolone). Symptoms of peripheral neuropathy and findings on electrophysiologic study gradually improved as well as headache and dry skin after discontinuation of ATRA, in spite of additional chemotherapy. The right abducens nerve palsy also partially improved.To the best of our knowledge, this is the first report of ATRA-induced multiple mononeuropathies. Neurological symptoms might be considered as atypical pseudotumor cerebri with focal neurological sign [5]. However, there was no evidence of intracranial hypertension. Furthermore, we carefully excluded a possibility that other medication including anticancer drugs induced peripheral neuropathy. Clinicia...
Metaiodobenzylguanidine scintigraphy and DAT SPECT are highly concordant with clinical diagnosis in differentiating DLB from other dementias. However, given the limitations in the study design, the applicability of these results to real-world differential diagnosis remains unclear. Prospective studies targeting patients with atypical presentations that adopt gold standard tests would reliably estimate the true test performance of these promising biomarkers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.